| Drug NDC: | 17089-076 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Citomix |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Aldesleukin - Binetrakin - Canakinumab - Centella Asiatica - Cranberry - Human Interleukin-6 (nonglycosylated) - Interferon Gamma-1b - Lenograstim - Pineapple - Sus Scrofa Bone Marrow - Sus Scrofa Small Intestine Mucosa Lymph Follicle - Sus Scrofa Thymus - |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Guna Spa |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Pellet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ALDESLEUKIN - 5 [hp_C]/4g BINETRAKIN - 4 [hp_C]/4g CANAKINUMAB - 5 [hp_C]/4g CENTELLA ASIATICA - 3 [hp_X]/4g CRANBERRY - 3 [hp_X]/4g HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - 7 [hp_C]/4g INTERFERON GAMMA-1B - 4 [hp_C]/4g LENOGRASTIM - 4 [hp_C]/4g PINEAPPLE - 3 [hp_X]/4g SUS SCROFA BONE MARROW - 4 [hp_C]/4g Load more... SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - 4 [hp_C]/4g SUS SCROFA THYMUS - 4 [hp_C]/4g |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 23 May, 2006 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 19 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Guna spa |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000178328 N0000009391 M0011506 N0000175667 N0000185371 N0000185375 N0000175629 N0000184306 M0000728 M0006342 M0016962 N0000185015 N0000175541 M0011490 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | M89N0Q7EQR 751635Z921 37CQ2C7X93 7M867G6T1U 0MVO31Q3QS 92QVL9080Y 21K6M2I7AG 6WS4C399GB 2A88ZO081O VP2CN2G7Y8 Load more... 308LM01C72 7B69B0BD62 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Lymphocyte Growth Factor [EPC] Non-Standardized Food Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] Interferon gamma [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Lymphocyte Activation [PE] Increased Lymphocyte Cell Production [PE] Increased Histamine Release [PE] Cell-mediated Immunity [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Interleukin-2 [CS] Allergens [CS] Dietary Proteins [CS] Plant Proteins [CS] Interferon-gamma [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Cell-mediated Immunity [PE] Dietary Proteins [CS] Fruit Proteins [EXT] Increased Histamine Release [PE] Increased Lymphocyte Activation [PE] Increased Lymphocyte Cell Production [PE] Interferon gamma [EPC] Interferon-gamma [CS] Interleukin-2 [CS] Lymphocyte Growth Factor [EPC] Non-Standardized Food Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] Plant Proteins [CS] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 17089-076-20 | 2 TUBE in 1 BOX (17089-076-20) / 4 g in 1 TUBE | 23 May, 2006 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.